Results 21 to 30 of about 29,794,370 (246)
The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression [PDF]
JCI Insight, 2023 Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic nephropathy, is characterized by phenotypic variability that exceeds genic effects. Dysregulated metabolism and immune cell function are key disease modifiers. The tryptophan
Dustin T. Nguyen +9 more
doaj +2 more sources
Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1 [PDF]
Journal of the American Chemical Society, 2018 Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dioxygenase (hTDO) catalyze the same dioxygenation reaction of Trp to generate N-formyl kynurenine (NFK). They share high structural similarity, especially in the active site. However, hIDO1 possesses a unique inhibitory substrate binding site (Si) that is absent in hTDO. In addition, in hIDO1,
Ariel Lewis-Ballester +4 more
+12 more sources
Frontiers in Immunology, 2021 Although melanoma remains the deadliest skin cancer, the current treatment has not resulted in the desired outcomes. Unlike chemotherapy, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy.
Mahdi Abdoli Shadbad +10 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-containing enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metabolism, which plays an important role in immunity and neuronal function.
Yu Yao +8 more
doaj +1 more source
Nature Communications, 2022 Indoleamine 2,3 dioxygenase-1 (IDO1) catalyzes tryptophan-kynurenine metabolism in many inflammatory and cancer diseases. Of note, acute inflammation that occurs immediately after heart injury is essential for neonatal cardiomyocyte proliferation and ...
Donghong Zhang +7 more
doaj +1 more source
Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Journal of Medicinal Chemistry, 2021 Since the discovery of the implication of indoleamine 2,3-dioxygenase 1 (IDO1) in tumoral immune resistance in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies, supported by the publication of the first crystal structure of IDO1 in 2006.
Röhrig, Ute F +2 more
openaire +4 more sources
Pathogens, 2022 Chikungunya virus (CHIKV) infection causes intense cytokine/chemokine inflammatory responses and debilitating joint pain. Indoleamine2,3–dioxygenase 1 (IDO-1) is an enzyme that initiates the tryptophan degradation that is important in initial host innate
Thiara Manuele Alves de Souza +16 more
doaj +1 more source
Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma [PDF]
, 2022 Introduction: Tumour-emitted molecules induce immunosuppression in the tumour microenvironment. An immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO/IDO1), facilitates immune escape in several malignant tumours, including osteosarcoma ...
Farooq, Asim +2 more
core +1 more source
Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold
Pharmaceuticals, 2021 Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one ...
Ana Dolšak +6 more
doaj +1 more source
Research progress of indoleamine 2,3-dioxygenase 1 in gastric cancer
生物医学转化, 2023 Gastric cancer is the fifth most common malignant tumor and fourth leading cause of cancerrelated deaths worldwide. Gastric cancer has obvious heterogeneity and complex tumor microenvironment. Although immune checkpoint inhibitors have shown certain anti-
Pei Xiaxia +6 more
doaj +1 more source